What can be expected from the pre-filled syringes market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
Our 206-page report provides 123 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall regional market and national level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and STEP analysis) and commercial developments.
See revenue forecasts for the leading submarkets and indications How will submarkets perform to 2026? Our study forecasts revenues in the following national submarkets: • National and Regional Markets • Leading Therapeutic Sectors • Leading Pre-Filled Device Therapies • Pre-Filled Syringe and Related Technology Manufacturers
Leading companies and potential for market growth Overall revenue for the Pre-filled syringe market will reach $6,940m in 2020, our work forecasts. We predict strong revenue growth through to 2026. A number of new injectable drugs and advances in technology are seen as factors driving growth over the forecast period.
Our work analyses the key companies in the market. See Visiongain’s analysis of 14 leading companies, including these: • Becton, Dickinson and Company • Gerresheimer • Schott • Baxter • Nipro • Weigao • Unilife • Roselabs • SHL Group • Ypsomed • Haselmeier • Owen Mumford • Bespak • Datwyler
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook • Company news relevant to the market • Historical revenues
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the Pre-Filled Syringe industry? Our new report discusses issues and events affecting the pre-filled syringe market. You will find discussions, including qualitative analyses on a range of topics. You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Pre-Filled Syringes Market 2016-2026 report helps you In summary, our 206-page report gives you the following knowledge: • Revenue forecasts to 2026 for the Pre-Filled Syringes market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2026 for the leading national markets – US, Japan, EU5, BRIC • Revenue forecasts to 2026 for submarkets – discover prospects for leading therapeutic areas, as well as products within these areas. Identify the key trends driving and restraining growth in the market, including government policy and economic conditions relevant to the market. • Assessment of 14 leading companies – historical revenue, news and upcoming product releases • Discussion of what stimulates and restrains the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the pre-filled syringes market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1. Global Pre-Filled Syringes Market Overview 1.2. Global Pre-Filled Syringes Market Segmentation 1.3. Why You Should Read This Report 1.4. How This Report Delivers 1.5. Key Questions Answered by This Analytical Report 1.6. Who is This Report For? 1.7. Methodology 1.8. Frequently Asked Questions (FAQ) 1.9. Associated Visiongain Reports 1.10. About Visiongain
2. Introduction to Pre-Filled Syringes 2.1. What are Pre-Filled Syringes? 2.2. A Brief History of Pre-Filled Syringes 2.3. Design and Manufacture of Pre-Filled Syringes 2.3.1. Glass and Plastic Syringes 2.3.2. Safety and the Pre-Filled Syringe Market 2.3.3. Concerns over Needlestick Injuries 2.4. An Introduction to Pen Injectors and Autoinjectors 2.4.1. Pen Injectors and Autoinjectors Offer Advantages in Self-Administration 2.4.2. What Determines Injection Device Choice? 2.5. Glass versus Plastic 2.5.1. Glass 2.5.2. Plastic 2.6. Future Directions for Pre-Filled Syringes 2.7. Pre-Filled Syringes: Market Segmentation 2.8. Scope of this Report 2.8.1. Products Excluded from this Report 2.9. Currency Exchange Rates in This Report
3. Pre-Filled Syringes: World Market 2016-2026 3.1. Pre-Filled Syringes as a Share of the Global Drug Delivery Market 3.2. The World Pre-Filled Syringes Market in 2015 3.2.1. World Pre-Filled Syringes Market: Market Shares by Segment 2015 3.2.2. Leading Companies in the Pre-Filled Syringes Market 3.3. World Pre-Filled Syringes Market: Sales Forecast by Value, 2016-2026 3.4. How Will Segmental Market Shares Change to 2026? 3.5. World Pre-Filled Syringes Market: Drivers and Restraints 2016-2026 3.5.1. Biologics and Biosimilars to Drive Market Growth 3.5.2. Human Factors and Regulatory Requirements 3.5.3. Advances in Pre-Filled Syringe Manufacturing 3.5.4. Market Genericisation and Pre-Filled Syringes 3.5.5. The Injectable Drug Pipeline is Substantial 3.5.6. Competing Drug Delivery Technologies 3.6. Glass Pre-Filled Syringes Lead the Pre-Filled Syringes Market 3.6.1. Glass Pre-Filled Syringes Market: Sales Forecast by Value, 2016-2026 3.6.2. Glass Pre-Filled Syringes: Drivers and Restraints 2016-2026 3.7. Plastic Pre-Filled Syringes: Rapid Growth Forecasted 3.7.1. Plastic Pre-Filled Syringes Market: Sales Forecast by Revenue, 2016-2026 3.7.2. Plastic Pre-Filled Syringes: Drivers and Restraints 2016-2026 3.8. Pen Injectors and Autoinjectors: A Growing Segment 3.8.1. Pen Injectors and Autoinjectors Market: Sales Forecast by Value, 2016-2026 3.8.2. Pen Injectors and Autoinjectors: Drivers and Restraints 2016-2026 3.8.3. Insulin and Other Biologics to Lead Market Growth
4. Leading National and Regional Markets 2016-2026 4.1. National Breakdown of the World Pre-Filled Syringes Market 4.2. World Pre-Filled Syringes Market: National Markets Forecast 2016-2026 4.2.1. How Will National Market Shares Change to 2026? 4.3. Regional Breakdown of the World Pre-Filled Syringes Market 4.4. World Pre-Filled Syringes Market: Regional Markets Forecast 2016-2026 4.4.1. How Will Regional Market Shares Change to 2026? 4.5. US Pre-Filled Syringes Market Forecast 2016-2026 4.5.1. US Pre-Filled Syringes Market: Trends and Developments 4.5.1.1. New Drug and Device Launches to Drive Growth to 2026 4.5.1.2. The Budget Control Act 2011 and the Medical Excise Tax 4.6. Japanese Pre-Filled Syringes Market Forecast 2016-2026 4.7. EU5 Pre-Filled Syringes Market Forecast 2016-2026 4.8. Emerging Markets: Pre-Filled Syringes Market Forecast 2016-2026 4.8.1. Pre-Filled Syringe Manufacturers Are Investing in Emerging Markets 4.8.2. Chinese Pre-Filled Syringes Market Forecast 2016-2026 4.8.3. Indian Pre-Filled Syringes Market Forecast 2016-2026 4.8.4. Russian Pre-Filled Syringes Market Forecast 2016-2026 4.8.5. Brazilian Pre-Filled Syringes Market Forecast 2016-2026
5. Leading Therapeutic Sectors for Pre-Filled Syringes 2016-2026 5.1. Leading Therapeutic Sectors for Pre-Filled Syringes and Other Injection Devices in 2015 5.1.1. Vaccines and Heparins Are Major Market Sectors 5.1.2. Rising Demand in Chronic Conditions: Autoimmune Diseases and Diabetes 5.1.3. Growth for Key Market Sectors 2016-2026 5.2. Pre-Filled Syringes and Pen Injectors for Diabetes 2016-2026 5.2.1. Insulin Market Forecast 2016-2026 5.2.2. High Rates of Pen Injector Use in the EU and Japan 5.2.3. Insulin Pumps: A Technology to Challenge Pen Injectors to 2026? 5.2.4. MannKind’s Afrezza: Inhalable Insulin Approved in US 5.2.5. Injection Devices for Biosimilar Insulin Products 5.3. Rheumatoid Arthritis: Leading Biologics Dominate the Market 5.3.1. Rheumatoid Arthritis Market Forecast 2016-2026 5.3.2. All Major Injectable Therapies Are Marketed in Proprietary Devices 5.3.3. Novel Injection Systems for RA: Meeting the Needs of Patients 5.3.4. The Receding Threat from Oral Therapies to 2026 5.4. Growth Hormones: Outlook to 2026 5.4.1. Growth Hormones Market Forecast 2016-2026 5.4.2. Biosimilar Growth Hormones and Pen Injectors 5.4.3. Uptake of Needle-Free Injectors for Growth Hormones 5.5. The Vaccine Market Outlook 2016-2026 5.5.1. Vaccine Market Forecast 2016-2026 5.5.2. Single-Use Devices for Vaccine Delivery 5.5.2.1. BD Uniject: A Private-Public Collaboration 5.5.3. Needle-Free Injectors for Vaccines 5.5.4. Other Trends in Vaccine Delivery 5.6. PCSK9 Inhibitors: The Next Advance in Cholesterol-Lowering Drugs 5.6.1. PCSK9 Inhibitors Market Forecast 2016-2026 5.6.2. PCSK9 Inhibitors and Pre-Filled Syringes/Injectors
6. Leading Pre-Filled Device Therapies 2016-2026 6.1. Leading Insulin Therapies Using Pen Injectors 2016-2026 6.1.1. Lantus: The World’s Best-Selling Insulin Analogue 6.1.1.1. SoloSTAR, ClikSTAR and AllSTAR: Three Pen Injectors for Lantus 6.1.1.2. Lantus: Sales Forecast 2016-2026 6.1.2. NovoLog: The Leading Fast-Acting Insulin 6.1.2.1. NovoLog FlexPen: To Be Retired 6.1.2.2. Novo’s New FlexTouch Pen Launched 6.1.2.3. NovoLog: Sales Forecast 2016-2026 6.1.3. Humalog 6.1.3.1. Humalog: HumaPen and KwikPen 6.1.3.2. Humalog: Sales Forecast 2016-2026 6.2. Top Biologics for Rheumatoid Arthritis: Device Outlook to 2026 6.2.1. Humira: The Biggest-Selling Drug in 2015 6.2.1.1. The Humira Pen Is an Innovative Delivery Device 6.2.1.2. Humira: Sales Forecast 2016-2026 6.2.2. Enbrel: The Leading Competitor to Humira 6.2.2.1. Pre-Filled Injection Devices Available for Enbrel in 2015 6.2.2.2. Enbrel: Sales Forecast 2016-2026 6.3. Growth Hormones: Two Products Dominated the Market in 2015 6.3.1. Norditropin: the Leading Growth Hormone 6.3.1.1. Norditropin: Sales Forecast 2016-2026 6.3.2. Genotropin: Sales Forecast 2016-2026 6.4. Outlook for Leading PCSK9 Products 2016-2026 6.4.1. Praluent (alirocumab, Sanofi/Regeneron) 6.4.1.1. Praluent: Sales Forecast 2016-2026 6.4.1.2. Amgen Suit Against Sanofi/Regeneron’s Praluent 6.4.2. Repatha (evolocumab, Amgen) 6.4.2.1. Repatha: Sales Forecast 2016-2026
7. Leading Pre-Filled Syringe and Related Technology Manufacturers, 2016 7.1. Leading Pre-Filled Syringe Manufacturers in 2015 7.1.1. Becton, Dickinson & Company: The Market Leader 7.1.1.1. Becton, Dickinson & Company: Pre-Filled Syringes Product Portfolio 7.1.1.2. BD Historical Revenue and Market Prospects 7.1.1.3. Recent Acquisitions by BD 7.1.1.4. BD Acquisition of CareFusion 7.1.1.5. BD AutoShield Duo Pen Needle Launched in 2014 7.1.2. Gerresheimer 7.1.2.1. Gerresheimer: Pre-Filled Syringes Product Portfolio 7.1.2.2. Gerresheimer Historical Revenue 2014-2015 and Market Outlook 7.1.2.3. Gerresheimer: Products in Development 7.1.2.4. Patent Application for Gerresheimer’s Gx G-Fix Adapter 7.1.2.5. Gerresheimer Commissioned to Manufacture Simponi Autoinjectors 7.1.2.6. Gerresheimer Opens First Development Center in China 7.1.3. Schott 7.1.3.1. Schott: Pre-Filled Syringes Product Portfolio 7.1.3.2. Schott Historical Revenue and Market Prospects 7.1.3.3. Schott: Expansion in India 7.2. Other Notable Pre-Filled Syringe Manufacturers 7.2.1. Baxter: Providing Contract Manufacturing with Pre-Filled Syringes 7.2.2. Nipro: Leading Japanese Contract Manufacturer 7.2.2.1. Nipro’s 2012 Acquisition of MGlas 7.2.3. Stevanato Group/Ompi: Insulin Vials Market Leader 7.2.4. Weigao: Pre-Filled Syringes for China and Beyond 7.2.5. Unilife: Pre-Filled Safety Syringes 7.2.6. Roselabs: Entered the Market in 2012 7.2.7. Vetter Pharma: Offering Lyo-Ject Dual-Chamber Syringes 7.2.8. Other Companies 7.3. Leading Pen Injector and Autoinjector Manufacturers in 2015 7.3.1. SHL Group 7.3.1.1. SHL Group: Pen Injectors and Autoinjectors Product Portfolio 7.3.1.2. SHL Group Market Prospects 7.3.2. Ypsomed 7.3.2.1. Ypsomed: Pen Injectors and Autoinjectors Product Portfolio 7.3.2.2. Ypsomed Historical Revenue and Market Prospects 7.3.2.3. Ypsomed: Recent Developments 7.3.3. Haselmeier 7.3.3.1. Haselmeier: Pen Injectors and Autoinjectors Product Portfolio 7.3.3.2. Haselmeier: Market Prospects 7.3.4. Owen Mumford 7.3.4.1. Owen Mumford: Pen Injectors and Autoinjectors Product Portfolio 7.3.5. Bespak: Entering the Auto-Injectors Market 7.3.6. Other Leading and Emerging Autoinjector Manufacturers 7.4. Leading Pre-Filled Syringe Component Manufacturers in 2016 7.4.1. Datwyler 7.4.1.1. Datwyler Historical Revenue and Market Prospects
8. Qualitative Analysis of the Pre-Filled Syringes Market 2016-2026 8.1. SWOT Analysis of the Pre-Filled Syringes Market 8.2. Strengths 8.2.1. Pre-Filled Syringes and Pen/Autoinjectors are Used In Chronic Conditions 8.2.2. Device Manufacturers Offer a Range Of Products 8.2.3. Customisation and Product Differentiation 8.2.4. Effective Lifecycle Management 8.3. Weaknesses 8.3.1. Patients with Needle Phobia 8.3.2. Chronic Diseases May Make Pre-Filled Syringes Difficult to Use 8.3.3. Risk of Extractables and Leachables 8.3.4. Higher Cost and Greater Cold Chain and Storage Requirements 8.4. Opportunities 8.4.1. Biosimilars Represent a Growing Market 8.4.2. Viscous and Large-Volume Drugs Require Novel Devices 8.4.3. Technological Developments Expanding Product Portfolios 8.4.4. Many Injectable Drugs in the Pipeline 8.4.5. Growth in Emerging Markets 8.5. Threats 8.5.1. Alternative Technologies: Needle-Free and Bolus Injectors 8.5.2. New Oral Therapies for Many Chronic Conditions 8.5.3. Increasing Regulatory Barriers 8.5.4. Cost Pressures on Healthcare Payers 8.6. STEP Analysis of the Pre-Filled Syringes Market 8.6.1. Social Factors: Rising Disease Incidence and Demand for At-Home Care 8.6.2. Technological Developments: Improved Safety and Administration 8.6.3. Economic Pressures: Pre-Filled Syringes Are Cost Efficient 8.6.3.1. High Barriers to Market Entry Exist 8.6.4. Political Issues: Regulatory Developments for Pre-Filled Syringes 8.7. Regulatory and Safety Outlook for Pre-Filled Syringes, 2016-2026 8.7.1. Needlestick Safety and Prevention 8.7.2. International Regulations for Needlestick Prevention 8.7.2.1. The US: The First Country to Introduce Needlestick Legislation 8.7.2.2. The EU: New Rules from 2013 Onwards 8.7.2.3. Needlestick Safety in Japan 8.7.2.4. Legislation for Needlestick Safety in Emerging Markets 8.7.3. Manufacturers Will Continue to Develop New Devices for Needlestick Prevention 8.7.3.1. Ancillary versus Integrated Safety Devices 8.7.4. Extractables and Leachables 8.7.4.1. Companies Will Reduce Sources of Extractables and Leachables 8.7.4.2. Products that Minimise Extractables and Leachables 8.7.4.3. Protein Aggregation: The Challenge of Biological Drugs 8.7.4.4. Regulatory Requirements for Extractables and Leachables 8.8. Biologics and the Pre-Filled Syringes Market, 2016-2026 8.8.1. Manufacturing Pre-Filled Syringes for Biologics: Glass versus Plastic 8.8.2. Biologics Provide New Challenges for Device Manufacturers 8.8.2.1. Lyophilised Drugs and Dual-Chamber Devices 8.8.3. Delivery Opportunities for High Viscosity Drugs 8.8.4. Are Biosimilars an Opportunity for Pre-Filled Syringe Manufacturers? 8.9. The Role of Patients in Pre-Filled Syringe Industry Development and Growth 8.9.1. Chronic Disease Incidence 2016-2026 8.9.2. The Rise in At-Home Care 8.9.3. Improving Patient Adherence 8.9.4. Injection Devices Must be Developed for Patient Convenience: Human Factors Engineering 8.10. Technological Developments in Pre-Filled Syringes to 2026 8.10.1. Product Differentiation Will be Vital in Crowded Treatment Markets 8.10.2. Product Customisation: Adapting Injection Devices 8.10.3. Trends in Manufacturing Materials for Pre-Filled Syringes 8.10.4. Competing Technologies Will Challenge Pre-Filled Syringes 8.10.4.1. Will Needle-Free Devices Become a Significant Competing Technology? 8.10.4.2. Patients Prefer Oral Drug Delivery 8.11. Outsourcing in the Pre-Filled Syringe Industry 8.11.1. Contract Medical Device Manufacturing 8.11.2. Contract Filling of Pre-Filled Syringes
9. Research Interviews 9.1. Interview with Nemera 9.1.1. Drivers and Restraints in the Pre-Filled Syringes Market 9.1.2. State of the Emerging Markets 9.1.3. Greatest Unmet Need in the Market 9.1.4. Therapeutic Areas Set to Benefit 9.1.5. Therapeutic Areas Set to Benefit 9.1.6. Nemera’s Safe’n’Sound Products 9.1.7. Other Nemera Products
10. Conclusions 10.1. Pre-Filled Syringes and Pen/Autoinjectors: Strong Growth Expected 10.2. The World Pre-Filled Syringes Market in 2015 10.2.1. Current Leading Pre-Filled Syringes Segments 10.2.2. Leading Pre-Filled Syringes Companies 10.2.3. Leading National and Regional Markets 10.3. World Pre-Filled Syringes Market Forecast 2016-2026 10.4. The Future of the Pre-Filled Syringes Market? 10.4.1. Glass Syringes Will Continue to Dominate 10.4.2. Innovation for Growth
11. Glossary
Appendix Visiongain’s Bespoke Research Service Some Associated Reports Visiongain Report Sales Order Form About Visiongain Report Evaluation Form
List of Tables Table 2.1 Currency Exchange Rates, 2015 Table 3.1 World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Segment, 2015-2026 Table 3.2 Market Shares (%) of Leading Pre-Filled Syringes Market Segments, by Revenue, 2015, 2020 and 2026 Table 3.3 Glass Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 3.4 Selected Proprietary Polymers for Plastic Pre-Filled Syringes, 2015 Table 3.5 Plastic Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 3.6 Pen Injectors and Autoinjectors Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 4.1 World Pre-Filled Syringes Market: Revenues ($m) and Market Shares (%) by National Market, 2015 Table 4.2 World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026 Table 4.2 World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026 (continued) Table 4.3 Market Shares (%) of Leading National Pre-Filled Syringes Markets, 2015, 2020 and 2026 Table 4.4 World Pre-Filled Syringes Market: Revenues ($m) and Market Shares (%) by Regional Market, 2015 Table 4.5 World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Regional Market, 2015-2026 Table 4.6 Market Shares (%) of Leading Regional Pre-Filled Syringes Markets, 2015, 2020 and 2026 Table 4.7 US Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 4.8 Japanese Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 4.9 EU5 Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026 Table 4.10 Chinese Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 4.11 Indian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 4.12 Russian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 4.13 Brazilian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 5.1 Pen Manufacturing Agreements for Leading Insulin Brand Manufacturers, 2015 Table 5.2 Selected Biosimilar Insulin Pen Injectors, 2016 Table 5.3 Insulin Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 5.4 Rheumatoid Arthritis Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 5.5 Growth Hormone Therapies in Pen Injectors, 2016 Table 5.6 Growth Hormones Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 5.7 Selected Biosimilar Growth Hormones in Emerging Markets, 2016 Table 5.8 Vaccines Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 5.9 PCSK9 Inhibitors Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.1 Leading Pre-Filled Insulin Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.2 Sanofi: Lantus Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.3 Novo Nordisk: NovoLog Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.4 Eli Lilly: Humalog Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.5 Leading Pre-Filled Rheumatoid Arthritis Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.6 AbbVie/Eisai: Humira Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.7 Amgen/Pfizer: Enbrel Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.8 Leading Pre-Filled Growth Hormone Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.9 Novo Nordisk: Norditropin Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.10 Pfizer: Genotropin Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.11 Sanofi: Praluent Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 6.12 Amgen: Repatha Revenue ($m), AGR (%) and CAGR (%), 2015-2026 Table 7.1 BD: Overview, 2016 Table 7.2 BD: Pre-Filled Injection Systems, 2016 Table 7.3 BD: Pharmaceutical Systems Revenue ($m), AGR (%), CAGR (%), 2010-2015 Table 7.4 Gerresheimer: Overview, 2016 Table 7.5 Gerresheimer: Plastics & Devices and Primary Packaging Glass Segment Revenue ($m) for 2014 and 2015, plus AGR (%) Table 7.6 Schott: Overview, 2016 Table 7.7 Schott: Net Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 7.8 Unilife: Pre-Filled Syringe Product Portfolio, 2016 Table 7.9 Unilife: Net Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 7.10 SHL Group: Overview, 2016 Table 7.11 SHL Group: Pen Injector and Autoinjector Portfolio, 2016 Table 7.12 Ypsomed: Overview, 2016 Table 7.13 Ypsomed: Pen Injector and Autoinjector Portfolio, 2016 Table 7.14 Ypsomed: Delivery Devices Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 7.15 Haselmeier: Overview, 2016 Table 7.16 Haselmeier: Pen Injector and Autoinjector Portfolio, 2016 Table 7.17 Owen Mumford: Overview, 2016 Table 7.18 Owen Mumford: Pen Injector and Autoinjector Portfolio, 2016 Table 7.19 Datwyler: Overview, 2016 Table 7.20 Datwyler: Pharma Packaging Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 8.1 Benefits and Weaknesses to Pre-Filled Syringes as an Injectable Delivery Device, 2016 Table 8.2 Pre-Filled Syringes Market: STEP Analysis, 2016-2026 Table 8.3 Selected Safety Products for Pre-Filled Syringes, 2016 Table 8.4 Selected Pre-Filled Injection Devices for Lyophilised Drugs, 2016 Table 8.5 Pre-Filled Syringe Manufacturers: Alternative Injectable Technologies, 2016 Table 8.6 Selected Insulin Pumps Available, 2016 Table 8.7 Oral Drug Competitors for Leading Pre-Filled Syringe Therapeutic Sectors, 2016-2026 Table 8.8 Selected Leading CMOs: Pre-Filled Syringe Filling Capabilities, 2016
List of Figures Figure 1.1 Global Pre-Filled Syringes Market Segmentation Overview, 2016 Figure 2.1 Diagram of Syringe Parts, 2015 Figure 2.2 Timeline of Pre-Filled Syringe Development, 1950-2015 Figure 2.3 Major Trends for Pre-Filled Syringe Market Growth, 2016 Figure 3.1 World Pre-Filled Syringes Market: Market Shares (%) by Segment, 2015 Figure 3.2 World Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 3.3 World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2015 Figure 3.4 World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2020 Figure 3.5 World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2026 Figure 3.6 World Pre-Filled Syringes Market: Drivers and Restraints, 2016-2026 Figure 3.7 Glass Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 3.8 Glass Pre-Filled Syringes Market: Drivers and Restraints, 2016-2026 Figure 3.9 Plastic Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 3.10 Plastic Pre-Filled Syringes Market: Drivers and Restraints, 2016-2026 Figure 3.11 Pen Injectors and Autoinjectors Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 3.12 Pen Injectors and Autoinjectors Market: Drivers and Restraints, 2016-2026 Figure 4.1 World Pre-Filled Syringes Market: Revenues ($m) by National Market, 2015 Figure 4.2 World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2015 Figure 4.3 World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2020 Figure 4.4 World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2026 Figure 4.5 World Pre-Filled Syringes Market: Revenues ($m) by Regional Market, 2015 Figure 4.6 World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2015 Figure 4.7 World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2020 Figure 4.8 World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2026 Figure 4.9 US Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 4.10 Japanese Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 4.11 EU5 Pre-Filled Syringes Market Forecast: Revenues ($m) by National Market, 2015-2026 Figure 4.12 Chinese Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 4.13 Indian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 4.14 Russian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 4.15 Brazilian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 5.1 Insulin Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 5.2 Rheumatoid Arthritis Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 5.3 Growth Hormones Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 5.4 Vaccines Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 5.5 PCSK9 Inhibitors Market Forecast: Revenues ($m) and AGR (%), 2015-2026 Figure 6.1 Sanofi: Lantus Revenue ($m) and AGR (%), 2015-2026 Figure 6.2 Novo Nordisk: NovoLog Revenue ($m) and AGR (%), 2015-2026 Figure 6.3 Eli Lilly: Humalog Revenue ($m) and AGR (%), 2015-2026 Figure 6.4 AbbVie/Eisai: Humira Revenue ($m) and AGR (%), 2015-2026 Figure 6.5 Amgen/Pfizer: Enbrel Revenue ($m) and AGR (%), 2015-2026 Figure 6.6 Novo Nordisk: Norditropin Revenue ($m) and AGR (%), 2015-2026 Figure 6.7 Pfizer: Genotropin Revenue ($m) and AGR (%), 2015-2026 Figure 6.8 Sanofi/Regeneron: Praluent Revenue ($m) and AGR (%), 2015-2026 Figure 6.9 Amgen: Repatha Revenue ($m) and AGR (%), 2015-2026 Figure 7.1 BD: Pharmaceutical Systems Revenue ($m), AGR (%), 2010-2015 Figure 7.2 Gerresheimer: Plastics & Devices and Primary Packaging Glass Segment Revenue ($m), 2014 and 2015 Figure 7.3 Schott: Net Revenue ($m) and AGR (%), 2010-2015 Figure 7.4 Unilife: Net Revenue ($m) and AGR (%), 2010-2015 Figure 7.5 Ypsomed: Delivery Devices Revenue ($m) and AGR (%), 2010-2015 Figure 7.6 Datwyler: Pharma Packaging Revenue ($m) and AGR (%), 2010-2015 Figure 8.1 Pre-Filled Syringes Market: Strengths and Weaknesses, 2016-2026 Figure 8.2 Pre-Filled Syringes Market: Opportunities and Threats, 2016-2026 Figure 10.1 World Pre-Filled Syringes Market Forecast: Revenues ($m) by Segment, 2015-2026
Abbvie Ache Amega Biotech Amgen Antares Pharma Aptar Stelmi AstraZeneca Baxter International Becton, Dickinson and Company Bespak Biocon Bioject Medical Technologies Biomarin Biosidus Boehringer Ingelheim Bristol-Myers Squibb Cambridge Consultants CareFusion Corporation Celgene Centocor Daikyo Seiko Datwyler Dong-A Dr. Reddy’s Eisai Pharmaceutical Eli Lilly Ferring Gan & Lee GeneScience Pharmaceuticals Gerresheimer GlaxoSmithKline Haselmeier Helvoet Pharmaceutical Hospira Incepta Pharmaceuticals Janssen Biotech Johnson and Johnson LG Life Sciences/Biopartners Mannkind Merck & Co Merck Serono Mitsubishi Tanabe Nektar Therapeutics Nipro Novartis Novo Nordisk OPKO Health Oval Medical Owen Mumford PA Consulting Group Palatin Technologies Pfizer PharmaJet Pharmstandard Polfa Tarchomin Regeneron Rhone Poulenc-Rorer Roehr Products Roselabs Bioscience Samsung Bioepis Sandoz Sanofi Schott Schott Kaisha Schott Xinkang Pharmaceutical Packaging SciGen Shanghai Celgen Bio-Pharmaceutical Shanghai CP Guojin SHL Group Square Pharmaceuticals Stevanato Group (Ompi) Takeda Pharmaceutical Terumo Teva Pharmaceutical Tonghua Dongbao UCB Unlife Vetter Vetter Pharma Weigao West Pharmaceuticals Wockhardt Ypsomed Zeon
Organisations Mentioned in the Report Battele Memorial Institute Carl Zeiss Foundation Centers for Disease Control (US) European Society of Cardiology National Health Service (UK) Parenteral Drug Association PATH UNICEF US Agency for International Development US Federal Drug Administration World Health Organization
Download sample pages
Complete the form below to download your free sample pages for Pre-Filled Syringes Market Forecast 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Pre-Filled Syringes Market Forecast 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
